Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.26 USD | +3.32% | +0.59% | -45.42% |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Apr. 22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.42% | 2.76B | |
+2.16% | 42.75B | |
+47.64% | 41.61B | |
+12.15% | 41.34B | |
-12.36% | 26.59B | |
+8.58% | 25.49B | |
-23.26% | 18.12B | |
+30.25% | 12.24B | |
-1.35% | 11.76B | |
+8.58% | 11B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours